Vera Therapeutics (VERA) Total Liabilities (2020 - 2026)

Vera Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $122.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 62.36% year-over-year to $122.0 million; the trailing twelve-month figure through Mar 2026 stood at $122.0 million (up 62.36% YoY), and the FY2025 full-year result was $130.2 million, up 65.82% from the prior year.
• Total Liabilities for Q1 2026 stood at $122.0 million, down from $130.2 million in the prior quarter.
• The five-year high for Total Liabilities was $130.2 million in Q4 2025, with the low at $25.7 million in Q3 2022.
• Historically, Total Liabilities has averaged $71.8 million across 5 years, with a median of $69.4 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 448.95% — and 2024, when it increased 6.32%.
• Vera Therapeutics' Total Liabilities stood at $54.5 million in 2022, then jumped by 35.46% to $73.9 million in 2023, then advanced by 6.32% to $78.5 million in 2024, then soared by 65.82% to $130.2 million in 2025, then fell by 6.27% to $122.0 million in 2026.
• The last three Total Liabilities figures came in at $122.0 million (Q1 2026), $130.2 million (Q4 2025), and $118.6 million (Q3 2025), per Business Quant data.